Rocatinlimab

6 trials

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

0 Recruiting

5 Completed trials

1 Sponsors

22 Countries

Phase III

Phase II

Phase III: 5 Phase II: 1

Oversight events:

2 serious breaches 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Sponsors using this IMP

All trials

6 total

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Phase III 9 countries Amgen Inc.
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Phase III 15 countries Amgen Inc.
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Phase II 5 countries Amgen Inc.
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Phase III 14 countries Amgen Inc.
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Phase III 11 countries Amgen Inc.
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Phase III 12 countries Amgen Inc.

Showing 1–6 of 6 trials

← All drugs A–Z